読み込み中
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
前日終値
$7.25
+$0.12 · +1.68%
日中の時刻はETです。市場データは遅延する場合があります。
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
日中レンジ
現在 $7.25
52週レンジ
現在 $7.25
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
72
割安
センチメント
54
まちまち
リスク
50
やや高いリスク
モメンタム
63
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
日中レンジ
現在 $7.25
52週レンジ
現在 $7.25
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.75億 USD | 5525.2万 USD | 68.2万 USD | — | — |
| 売上原価 | 2259.9万 USD | 797.3万 USD | 16.7万 USD | 62万 USD | 52.1万 USD |
| 粗利益 | 1.53億 USD | 4727.9万 USD | 51.5万 USD | −62万 USD | −52.1万 USD |
| 研究開発 | 3278万 USD | 3408.2万 USD | 4989.9万 USD | 7144.1万 USD | 7233.8万 USD |
| 販売・一般管理 | 2.8億 USD | 2.91億 USD | 1.18億 USD | 1億 USD | 6222.1万 USD |
| 営業費用 | 3.12億 USD | 3.25億 USD | 1.68億 USD | 1.72億 USD | 1.35億 USD |
| 受取利息 | 704.4万 USD | 1515.8万 USD | 787.6万 USD | 213.2万 USD | 4.1万 USD |
| 支払利息 | 6811.5万 USD | 7200.9万 USD | 4196.8万 USD | 2730.5万 USD | 678.8万 USD |
| 減価償却費と償却費 | 63.3万 USD | 79.5万 USD | 57.5万 USD | 62万 USD | 52.1万 USD |
| 営業利益 | −1.6億 USD | −2.77億 USD | −1.67億 USD | −1.72億 USD | −1.35億 USD |
| 純利益 | −2.21億 USD | −3.34億 USD | −2.02億 USD | −1.98億 USD | −1.44億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$17.60
上昇余地（142.76%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1921.34万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM932.17万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF568.32万0.01%954億 USD0.05%$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH524.08万1.14%4.62億 USD0.35%$64.65+1.60%
iShares Biotechnology ETFIBB281.82万0.03%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO270.51万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA217.67万0.01%218.24億 USD0.03%$32.79+0.40%
Simplify Propel Opportunities ETFSURI180.72万2.38%7606.44万 USD2.82%$17.06-0.14%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHASimplify Propel Opportunities ETFSURIAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
